Artivion (AORT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Executive summary
Annual meeting scheduled for May 12, 2026, at 9:00 a.m. Eastern Time, to be held virtually.
Proxy materials, including the Notice, Proxy Statement, proxy card, and Annual Report, are available online for review and voting.
Shareholders can vote online, by phone, by mail, or virtually at the meeting.
Voting matters and shareholder proposals
Election of nine directors: Thomas F. Ackerman, Daniel J. Bevevino, Marna P. Borgstrom, James W. Bullock, Jeffrey H. Burbank, Elizabeth A. Hoff, J. Patrick Mackin, Jon W. Salveson, and Anthony B. Semedo.
Advisory (non-binding) vote to approve compensation of Named Executive Officers as disclosed in the proxy materials.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxies may vote on other matters that may properly come before the meeting at their discretion.
Board of directors and corporate governance
Board recommends voting for all director nominees and for all proposals presented.
Instructions provided for withholding authority for individual director nominees.
Latest events from Artivion
- Q3 2024 revenue up 10% and EBITDA up 28%, led by product and global expansion.AORT
Q3 20249 Jul 2026 - Q1 revenue up 4% with strong product growth; guidance raised despite cyber-related headwinds.AORT
Q1 20259 Jul 2026 - Double-digit revenue and EBITDA growth expected in 2025, driven by innovation and global expansion.AORT
Q4 20248 Jul 2026 - Aortic-focused innovation and strong execution drive double-digit growth and margin expansion.AORT
Stifel 2025 Healthcare Conference8 Jul 2026 - AMDS and NEXUS launches drive growth in a $2B global aortic arch market.AORT
Truist Securities MedTech Conference 202616 Jun 2026 - Q1 2026 revenue up 18% to $116.3M; Endospan acquisition and NEXUS approval drive future growth.AORT
Q1 20268 May 2026 - Double-digit growth driven by On-X valves, stent grafts, and strong clinical outcomes.AORT
Corporate presentation8 May 2026 - Strong 2025 growth and robust 2026 outlook with double-digit revenue and EBITDA gains projected.AORT
Q4 202515 Apr 2026 - Proxy covers director elections, executive pay, auditor ratification, and ESG priorities.AORT
Proxy filing1 Apr 2026